Foundation Medicine

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's clinical assays, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer.
Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
2010
Size (employees)
535 (est)
Foundation Medicine was founded in 2010 and is headquartered in Cambridge, US

Key People at Foundation Medicine

Michael J. Pellini

Michael J. Pellini

President & CEO & Board Director
Steven J. Kafka

Steven J. Kafka

Chief Business Officer
Alexis Borisy

Alexis Borisy

Co - Founder & Chairman of the Board
Vincent A. Miller

Vincent A. Miller

SVP, Clinical Development

Foundation Medicine Office Locations

Foundation Medicine has an office in Cambridge
Cambridge, US (HQ)
150 Second St

Foundation Medicine Data and Metrics

Foundation Medicine Financial Metrics

Foundation Medicine's revenue was reported to be $16.7 m in Q1, 2017
USD

Revenue (Q1, 2017)

16.7 m

Gross profit (Q1, 2017)

(436 k)

Gross profit margin (Q1, 2017), %

(3%)

Net income (Q1, 2017)

(46.5 m)

EBIT (Q1, 2017)

(46.7 m)

Market capitalization (21-Sep-2017)

1.4 b

Cash (31-Mar-2017)

49.1 m
Foundation Medicine's current market capitalization is $1.4 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

29 m61.1 m93.2 m116.9 m

Revenue growth, %

111%53%25%

Cost of goods sold

11.7 m27.4 m36.7 m53 m

Gross profit

17.3 m33.6 m56.5 m63.9 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

14.5 m16.4 m19.3 m18.3 m21 m17.4 m20.7 m16.3 m16.7 m

Cost of goods sold

6.6 m7.5 m8.9 m9 m9.1 m10 m11.5 m14.7 m17.1 m

Gross profit

7.9 m8.9 m10.4 m9.4 m11.9 m7.4 m9.2 m1.6 m(436 k)

Gross profit Margin, %

54%54%54%51%57%42%45%10%(3%)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

124.3 m72.1 m117.8 m63.6 m

Accounts Receivable

6.3 m9.9 m7.4 m8.2 m

Inventories

992 k2.9 m6.5 m10.4 m

Current Assets

133.3 m89.6 m229.6 m168.9 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

97.1 m86.7 m61.7 m263.6 m250.2 m86.1 m62.3 m77.8 m49.1 m

Accounts Receivable

6.1 m6 m10.7 m5.9 m

Inventories

2.6 m4.2 m4.5 m6.1 m9.5 m6.7 m10.2 m12 m10.3 m

Current Assets

106.9 m98.3 m80.8 m289.5 m275.8 m235.9 m216.8 m196.5 m125.5 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(42.9 m)(52.2 m)(89.6 m)(113.2 m)

Depreciation and Amortization

5 m8.2 m10.6 m15.9 m

Accounts Receivable

(4.1 m)(3.6 m)2.4 m(844 k)

Inventories

(442 k)(1.9 m)(3.7 m)(2.4 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(13.8 m)(13 m)(17 m)(33.1 m)(20.6 m)(17.3 m)(29 m)(31.3 m)(46.5 m)

Accounts Receivable

6.1 m6 m10.7 m5.9 m

Inventories

2.6 m4.2 m4.5 m6.1 m9.5 m6.7 m10.2 m12 m10.3 m

Accounts Payable

5.5 m5.5 m9.4 m9.4 m12 m8.5 m10.8 m12 m10.4 m
USDY, 2017

Revenue/Employee

31.2 k

Financial Leverage

1.3 x
Show all financial metrics

Foundation Medicine Operating Metrics

Foundation Medicine's Customers was reported to be 30 in FY, 2016
FY, 2016

Products

5

Customers

30

Facilities

4
Show all operating metrics

Foundation Medicine Market Value History

Foundation Medicine Revenue Breakdown

Foundation Medicine Median Salaries

Source: 15 public H-1B filings from Foundation Medicine

Traffic Overview of Foundation Medicine

Foundation Medicine Online and Social Media Presence

Foundation Medicine News and Updates

Investors including Google Ventures poured $93 million into a company that's building personalized cancer vaccines

A biotech company that's developing personalized cancer treatments just raised $93 million to get their drugs into human trials. Gritstone Oncology is working on a type of cancer immunotherapy called cancer vaccines that seeks to help amplify the body's immune system to fig…

GV’s Tom Hulme on AI, life sciences, and Alphabet VC’s future in Europe

 GV — the VC owned by Google’s Alphabet and formerly known as Google Ventures — has had a few ups and downs in Europe since first setting up its stall here in London in 2014. It initially stormed into the market with $125 million to invest in its first year, along with four permanent partners (Tom H…

There's now a genetic test for women's fertility called Fertilome

It seems these days that there's a DNA test for everything — from your wine preferences to testing for what "superhero" genetic variants you might have. And for those interested in seeing how that genetic information could inform their health, the field is starting to expand…

Seven Bridges to Present on Cancer Moonshot’s Blood Profiling Atlas at Precision Medicine World Congress

PRESS RELEASE: Seven Bridges, the biomedical data analysis company, today announced that its Senior VP of Commercial Operations, Bruce Press, will join Dr. Howard Scher of Memorial Sloan Kettering Cancer Center and Dr. Geoff Otto of Foundation...

Boston Millennia Partners Invests in Cota, Inc.

PRESS RELEASE: Boston Millennia Partners is pleased to announce its investment in Cota, Inc. as part of an $18 million growth equity round. Cota is a New York City based cancer outcomes and data tracking company that uses a patented digital classification...
Show more

Foundation Medicine Company Life and Culture

You may also be interested in